Seeking Alpha

Empagliflozin, a treatment for type 2 diabetes that's being developed by Eli Lilly (LLY -1.3%)...

Empagliflozin, a treatment for type 2 diabetes that's being developed by Eli Lilly (LLY -1.3%) and Boehringer Ingelheim, improved blood glucose levels and met the the primary goals of four Phase III studies. In total, the program comprises eight multinational trials. Eli Lilly and Boehringer intend to file for regulatory review in the U.S., Europe and Japan in 2013. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs